Ion Channels - New opportunities for an established therapeutic target class By Dr Andrew Southan, Iain F. James and David Cronk There is an increasing recognition within the pharmaceutical industry of the immense potential for ion channels as a drug target class. Advances in the understanding of the human genome, combined with the introduction of [...]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!